Ed Miner, MD, FACC
Utah, Chapter President
ACC Governor, Utah

Join your colleagues from Idaho, Nevada, New Mexico, Utah, and Wyoming on September 6th and 7th for a weekend of hot topics in cardiovascular care including heart failure, amyloid, prevention, clinician wellness, atrial fibrillation, and more! CME/CNE/MOC credits will be provided. We look forward to a wonderful weekend of networking and learning together at the Park City, Utah. For more information and to register, please visit: ACC Rockies Chapter Meeting 2024

ACC Live Courses
For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings

RSS Latest in Cardiology from ACC.org

  • ZENITH: Sotatercept Effectively Reduces Composite Outcome in High-Risk PAH
    Sotatercept, a first-in-class novel activin-signaling inhibitor, led to a 76% lower risk of a composite of death from any cause, lung transplantation or hospitalization for worsening pulmonary arterial hypertension (PAH) compared to placebo in high-risk adults with PAH, according to results from the ZENITH study presented during a Clinical and Investigative Horizons session at ACC.25 […]
  • SUMMIT: No Impact From Baseline eGFR on HF Outcomes With Tirzepatide
    Among patients with obesity-related heart failure with preserved ejection fraction (HFpEF) and chronic kidney disease (CKD), the baseline estimated glomerular filtration rate (eGFR) did not impact the effect of tirzepatide on reducing major adverse HF events or to enhance health status, according to a post-hoc analysis of the SUMMIT trial presented during a Featured Clinical […]
  • PROLONG-ANG3: Solbinsiran May Lower apoB in Patients With Mixed Dyslipidemia
    Solbinsiran at the 400 mg dose reduced apolipoprotein B (apoB) concentration in patients with mixed dyslipidemia, according to research presented during a Featured Clinical Research session at ACC.25 in Chicago and simultaneously published in The Lancet.
  • Study on Early Intra-Aortic Balloon Pump Placement in Acute Decompensated Heart Failure Complicated by Cardiogenic Shock
    The goal of the Altshock-2 trial was to evaluate the effect of early intra-aortic balloon pump (IABP) use vs. standard care on 60-day survival or successful bridging to heart replacement therapies (HRT) in patients with heart failure–cardiogenic shock (HF-CS).
  • Risk Factor Modifications Quantified For Extending Life-Years Free of CVD, Death
    One of the most significant modifications that middle-aged patients can take to prevent cardiovascular disease is lowering arterial hypertension, according to research presented during a Featured Clinical Research Session at ACC.25 in Chicago and simultaneously published in NEJM. At 50 years of age, absence of uncontrolled hypertension and four other cardiovascular risk factors was associated […]